Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected
Dosani T, Covut F, Pinto R, Kim BG, Ali N, Beck R, Maitta R, Downes K, Fox R, Reese J, de Lima M, Malek E. Impact of lenalidomide on collected hematopoietic myeloid and erythroid progenitors: peripheral stem cell collection may not be affected. Leukemia & Lymphoma 2019, 60: 2199-2206. PMID: 30845862, DOI: 10.1080/10428194.2019.1573367.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutograftsBenzylaminesChemotherapy, AdjuvantCyclamsFemaleHematopoietic Stem Cell MobilizationHeterocyclic CompoundsHumansInduction ChemotherapyLenalidomideLeukapheresisMaleMiddle AgedMultiple MyelomaNeoadjuvant TherapyPeripheral Blood Stem Cell TransplantationRegression AnalysisRetrospective StudiesTransplantation, AutologousTreatment OutcomeConceptsImpact of lenalidomideLens exposureClinical implicationsPeripheral stem cell collectionAutologous stem cell transplantationTransplant-eligible patientsStem cell transplantationStem cell collectionSignificant clinical implicationsErythroid progenitorsHematopoietic myeloidInduction therapyLens usePBSC graftsCell transplantationMultiple myelomaPBSC collectionPlerixafor useLenalidomidePatientsCell collectionGraftMobilization agentsHematopoietic progenitorsExposure